Anupam Rasayan Appoints Hetvi Vyas as Deputy CFO and Key Managerial Personnel

What Happened

Anupam Rasayan China Pharmaceuticals (India) Limited, a listed specialty chemicals and pharmaceutical intermediates manufacturer, has formally appointed Hetvi Vyas to the dual role of Deputy Chief Financial Officer (Deputy CFO) and Key Managerial Personnel effective immediately. The appointment marks a substantive elevation within the company's financial leadership structure, positioning Vyas as a critical member of the senior management cadre.

As Deputy CFO, Vyas will assume responsibility for financial operations, reporting, internal controls, and strategic financial planning—functions increasingly critical in listed entities subject to heightened regulatory scrutiny. Her concurrent designation as Key Managerial Personnel under Section 203 of the Companies Act, 2013 carries statutory significance, placing her within the defined circle of senior executives responsible for corporate governance and accountability.

The announcement has been made public through stock exchange filings and regulatory disclosures as required under SEBI's listing obligations and the Companies Act framework. Such appointments typically follow board-level approval and are documented through board resolutions, regulatory filings with the Registrar of Companies (RoC), and stock exchange notifications to the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).

Why It Matters

This appointment carries implications across multiple regulatory and governance dimensions. Under MCA regulations, the designation of an individual as Key Managerial Personnel triggers mandatory disclosure requirements, board accountability frameworks, and statutory responsibilities. KMPs are bound by specific duties under the Companies Act, including fiduciary obligations to the company and requirements for disclosure of personal interests in transactions.

For finance professionals and compliance teams, the appointment underscores the evolving expectations around the CFO function in listed companies. Deputy CFO roles have become increasingly prominent as regulatory bodies emphasise layered accountability and succession planning. The dual designation signals that Vyas will bear statutory accountability for financial disclosures, internal control certification, and governance compliance—responsibilities that extend beyond operational finance into legal and regulatory domains.

From a corporate governance perspective, the appointment demonstrates Anupam Rasayan's approach to building robust financial leadership. Listed companies are expected to maintain clear hierarchies within finance functions with defined reporting lines, segregation of duties, and adequate bench strength. The creation or formalisation of a Deputy CFO position is often viewed by auditors, regulators, and market participants as evidence of institutionalised financial management rather than reliance on a single executive.

For audit and compliance teams, this development is material. Internal audit and compliance functions must update their understanding of reporting relationships, delegation of financial authority, and control ownership. External auditors will need to reassess management capability and potential changes to the control environment around financial reporting.

Practical Impact

Anupam Rasayan's finance and compliance teams must immediately ensure that Vyas's appointment is reflected across all regulatory frameworks. This includes updating board committee memberships (particularly the Audit Committee if applicable), revising authority matrices and delegation documents, and notifying internal stakeholders of revised approval hierarchies. The company must file the appointment notification with the RoC within the prescribed timeline—typically 30 days from the date of appointment—along with the prescribed forms and director/KMP remuneration disclosures if applicable.

From a compliance standpoint, all stock exchange notifications must be filed within 24 hours of the board decision, including updated organisational charts where required. The appointment may trigger updates to the Board of Directors' statement and management discussion & analysis in periodic regulatory filings. Listed companies must also disclose KMP remuneration details in their annual reports under Schedule V of the Companies Act and relevant SEBI regulations.

For Vyas herself, the designation carries personal statutory responsibility. She must ensure familiarity with her duties under Sections 166 and 203 of the Companies Act, including the duty to exercise due diligence, act in good faith, and report material irregularities. She will be bound by the code of conduct for KMPs and must disclose any potential conflicts of interest to the Board.

For investors and external stakeholders, this appointment provides reassurance of structural depth in financial governance but may also prompt questions about the predecessor's role and any ongoing transitions. Auditors should conduct appropriate procedures to assess management changes' impact on control design and operating effectiveness. The appointment should feature in Board evaluation processes and corporate governance self-assessments undertaken by listed entities for annual compliance certification.

Key Takeaways

• →Hetvi Vyas's dual designation as Deputy CFO and Key Managerial Personnel triggers mandatory disclosures under the Companies Act, 2013 and SEBI listing regulations, requiring RoC and stock exchange filings within prescribed timelines
• →Finance teams must immediately update authority matrices, delegation documents, and internal control documentation to reflect the new reporting hierarchy and approval structures
• →As a designated KMP, Vyas bears statutory accountability for financial disclosures, internal controls, and governance compliance, with personal liability exposure under Sections 166 and 203 of the Companies Act
• →Audit committees and internal audit functions must reassess the control environment, management capability, and financial reporting processes in light of the leadership restructuring
• →Annual report disclosures, remuneration schedules, and board committee compositions must be updated to reflect Vyas's role, with material disclosure in governance statements and MD&A sections

Disclaimer: This update is for general information only and does not constitute legal, tax or professional advice. Regulatory positions may change. Please consult APRA & Associates LLP for advice specific to your business. Contact us.